Taris Biomedical, a Lexington company focused on drug delivery systems for the bladder, said Wednesday that it has entered into a research collaboration with the large Anglo-Swedish drug maker AstraZeneca to evaluate novel treatments for bladder cancer.
On its website, Taris notes that traditional approaches to treating bladder diseases have largely proven to be insufficient, and in many cases extremely uncomfortable. To improve treatment, Taris has developed an approach designed to deliver therapeutics directly to the bladder continuously, and provide sustained relief for periods of weeks to months.
In a statement included in Wednesday’s press release, company president and chief executive Purnanand Sarma said: “Through this collaboration, Taris will have the opportunity to evaluate its proprietary bladder delivery platform in an oncology setting, potentially providing multiple novel product candidates to treat bladder cancer. Treatment options in bladder cancer are poor, and we believe our technology has the potential to revolutionize the treatment in this area. Collaboration with AstraZeneca is a validation of the potential of our technology and leverages the Taris know-how in bladder delivery and bladder cancer, one of the several therapeutic areas of focus for the company.”
In April, Taris announced that it had raised an additional $12.5 million financing round through its existing investors --- Flagship Ventures, Flybridge Capital Partners, Polaris Partners, and Third Rock Ventures. At the time, Taris said it had raised a total of $49.8 million to date.